Cyclerion Therapeutics

CYCN

Market cap $15.6M

CYCN Hedge Fund Activity: Q1 2026 in Review

17 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q1 2026, worth a combined $249K — down 34% from $376K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CYCN and 5 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.

The largest buyer was Geode Capital Management, adding an estimated $58.7K. The largest seller was Siren LLC, exiting entirely with an estimated $147K sold.

• 17 institutional investors held Cyclerion Therapeutics (CYCN) as of Q1 2026, down from 19 in Q4 2025.
• Funds reported $249K of Cyclerion Therapeutics stock for Q1 2026, down 34% quarter-over-quarter.
• 5 funds opened new Cyclerion Therapeutics positions in Q1 2026 and 6 closed out, a net change of -1 holder.
• The largest Cyclerion Therapeutics buyer in Q1 2026 was Geode Capital Management, an estimated $58.7K added.
• The largest Cyclerion Therapeutics seller in Q1 2026 was Siren LLC, an estimated $147K sold.

Based on aggregated 13F filings for Q1 2026.